Influenza Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Influenza Therapeutics Market is segmented By Disease Type (Influenza Type A, Influenza Type B, Influenza Type C, Influenza Type D), By Therapeutics (Medication, Vaccines, Others), By Route of Administration (Oral, Inhaled, Injectables), By End User (Hospitals and Clinics, Specialty Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Influenza Therapeutics Market Overview

Global Influenza Therapeutics Market is expected to reach at a high CAGR during the forecast period 2024-2031.

Influenza is a flu-like illness caused by the influenza virus with symptoms such as chills, fever, etc. Most people contract the flu by breathing in tiny airborne droplets from the coughs or sneezes of already infected patients. The Centers for Disease Control and Prevention recommends people get flu shots annually to prevent serious risks that lead to death. 

Outbreaks of influenza occur every year, and many people with flu-like symptoms use over-the-counter medication such as anti-viral drugs, anti-microbial drugs, etc. According to the World Health Organization (WHO), the annual global influenza attack rate ranges from 20% to 30% of the child population and around 10% of the adult population. The number of deaths due to influenza is approximately 290,000–650,000 annually.  

Influenza Therapeutics Market Scope

For more details on this report Request for Sample

Influenza Therapeutics Market Dynamics

Increasing clinical trials

Clinical trials are ongoing for vaccines, testing their safety, immunogenicity, and efficacy profiles. These vaccines are developed to increase efficacy and safety and decrease the harmful effects. For instance, according to clinical.gov, Mahidol University and the Government Pharmaceutical Organization conduct phase 3 clinical trials to evaluate the immunogenicity and safety of Tri Fluvac, a seasonal trivalent inactivated split virion influenza vaccine. The start date is August 3, 2020. The estimated completion date is December 31, 2023. 

The National Institute of Allergy and Infectious Diseases (NIAID) is conducting a phase 1 clinical trial to assess the safety and tolerability of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults. The start date is August 9, 2023. The estimated completion date is December 16, 2024. 

Nanjing Zenshine Pharmaceuticals conducts phase 2 and 3 trials to compare ZX-7101A in Chinese adult patients with uncomplicated influenza. The safety and efficacy of ZX-7101A is also assessed. The study start date is September 17, 2022. The estimated completion date is June 30, 2024.

Side effects of anti viral drugs 

Influenza drug side effects are mild and treatable, such as nausea and vomiting. Few anti-viral drugs cause bronchospasm as well as diarrhea. Oral oseltamivir is recommended for pregnant women as other medications like Baloxavir have severe complications when taken by pregnant women or breastfeeding women, as there is no safety data available for this drug. Due to the underlying risks, Zanamivir is approved for early flu treatment in people seven years and older.

Influenza Therapeutics Market Segment Analysis

The global influenza therapeutics market is segmented based on disease type, therapeutics, route of administration end user and region.

The  vaccines segment accounted for approximately 52.3% of the market share 

Vaccines are the most effective treatment for influenza compared to drugs, as vaccines give long-term protection to the patient. mRNA vaccines work more precisely and quickly as they destroy the primary target and cure the disease. Vaccine manufacturers like Pfizer and Moderna are working on the launch of mRNA vaccines for influenza.

In September 2022,  Pfizer Inc. initiated clinical trial phase 3 to evaluate the efficacy, tolerability, and immunogenicity of quadrivalent modified RNA (modRNA) influenza vaccine. 

In February 2023, Moderna initiated a phase 3 clinical trial to assess the safety and efficacy of mRNA-1010, a seasonal influenza vaccine candidate.

Global Influenza Therapeutics Market Geographical Share

North America accounted for approximately 41.2% of the market share in 2022

North America is expected to hold the largest share in the market owing to the presence of giant vaccine manufacturers such as Pfizer, moderna, etc., and the increasing prevalence of the disease in the US, Canada, etc. Several people from flu belong to the North American region. 

Influenza is a contagious disease which affects more that affects nearly 8% of the U.S. population annually. According to the World Health Organization (WHO), Seasonal influenza leads to an estimated 650,000 deaths worldwide yearly. More than 90% of influenza deaths occur in adults at least 65. 

According to the Government of Canada's annual report on seasonal influenza, During the 2021–2022 influenza season, 16,126 laboratory-confirmed influenza detections were reported out of 751,900 total laboratory tests. Nearly 71% of seniors (65 and older) are affected by influenza yearly.  

COVID-19 Impact Analysis

COVID-19 has significantly impacted the influenza therapeutics market as there is a shift in the focus on developing vaccines and drugs for the treatment of covid 19. Lockdowns are implemented worldwide, which halted many processes like supply chain and doctor visits. Diagnosis and treatment of influenza were postponed due to the fear of contracting the infection. As there was an emergency in the COVID-19 vaccine development, the other research activities were stopped by government authorities.

Influenza Therapeutics Market Companies

The major global players in the influenza therapeutics market include Merck KGaA, Santa Cruz Biotechnology, Inc., Biosynth, Teva Pharmaceuticals USA, Inc., Biorbyt Ltd., Thermo Fisher Scientific Inc., Steris, Healthcare PVT Ltd., Genentech, Inc., Lupin Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc. among others.

Key Developments

• In March 2023, eMed launched Urgent Care Telehealth Kit to enable same-day clinical evaluation and prescription medicine for four common illnesses which include Covid 19, influenza, urinary tract infection (UTI), and strep throat.  
• In September 2023, Clover Biopharmaceuticals, Ltd. launched AdimFlu-S (QIS) in China, the only imported quadrivalent flu vaccine approved for use in individuals aged 3 years and older.

Why Purchase the Report?

• To visualize the global influenza therapeutics market segmentation based on disease type, therapeutics, route of administration, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of influenza therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global influenza therapeutics market report would provide approximately 69 tables, 67 figures, and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies